Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Johnson & Johnson CFO on earnings: Guidance has 'a lot more than meets the eye'
07:28am, Tuesday, 15'th Apr 2025
Joseph Wolk, Johnson & Johnson EVP and CFO, joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's planned expenditures, and much more.
Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook
07:06am, Tuesday, 15'th Apr 2025
Johnson & Johnson (JNJ) on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year.
J&J Increases Outlook After Beating 1Q Expectations
06:53am, Tuesday, 15'th Apr 2025
Johnson & Johnson now expects sales of up to $91.8 billion in 2025, compared with a prior view of up to $90 billion.
J&J beats Wall Street quarterly sales and profit estimates on cancer drug sales
06:23am, Tuesday, 15'th Apr 2025
Johnson & Johnson on Tuesday reported first-quarter revenue and profit above Wall Street estimates, driven again by strong sales of its cancer treatments including multiple myeloma medicine Darzalex.
Johnson & Johnson Reports Q1 2025 Results
06:20am, Tuesday, 15'th Apr 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson's uniquely diversified portfolio was on full displ
Johnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
03:33am, Tuesday, 15'th Apr 2025
Johnson & Johnson JNJ will release earnings results for the first quarter, before the opening bell on Tuesday, April 15.
Trump Says Pharmaceutical Tariffs Coming in Near Future
02:03pm, Monday, 14'th Apr 2025
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with repo
Trump says US pharma tariffs coming in not-too-distant future
12:26pm, Monday, 14'th Apr 2025
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Perceived first-line utility, patient pool expansion, and paradigm-shifting potential distinguish Icotrokinra in the eyes of US dermatologists Perceived first-line utility, patient pool expansion, and
Jim Cramer's week ahead: Earnings from Goldman Sachs, Johnson & Johnson and Netflix
06:56pm, Friday, 11'th Apr 2025
CNBC's Jim Cramer on Friday told investors which market-moving events to follow next week. He pinpointed earnings reports from major banks like Goldman Sachs, as well as Johnson & Johnson and Netflix,
Johnson & Johnson: Fairly Valued, But Recession-Resilient
12:46pm, Friday, 11'th Apr 2025
Johnson & Johnson offers stability and limited downside risk, making it a solid investment in volatile markets, despite not being a high-growth stock. The company's fiscal 2024 results showed moderate
Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings
12:35pm, Friday, 11'th Apr 2025
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. We do not expect any improvement in MedTech sales.
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
10:30am, Friday, 11'th Apr 2025
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told
This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.
08:28am, Friday, 11'th Apr 2025
The Company spend billions to produce 100% of its key medicines for Americans in the U.S.
2 Top Dividend Stocks to Buy Right Now
04:25am, Friday, 11'th Apr 2025
Microsoft (MSFT -2.33%) and Johnson & Johnson (JNJ -1.64%) are leading companies in their respective industries. They both have impressive track records and have made their long-term shareholders sign
